ArticleJournal of geriatric oncology2019
Frailty assessment predicts toxicity during first cycle chemotherapy for advanced lung cancer regardless of chronologic age.
Article in Journal of geriatric oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06448455 (Observation of Frailty in Lung Cancer Patients and Its Influencing Factors), which is not on this map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observation of Frailty in Lung Cancer Patients and Its Influencing Factors
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The prognostic value of physical functioning on survival in patients with nonsmall cell lung cancer: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Predictive Value of Frailty on Outcomes of Patients With Cirrhosis: Systematic Review and Meta-Analysis.JMIR medical informatics · 2025Pooled it
- Associations of frailty with symptoms, and HRQOL in older cancer survivors after cancer treatments: a systematic review and meta-analyses.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- Impacts of Frailty on Prognosis in Lung Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Longitudinal identification of sentinel symptoms across frailty dimensions in lung cancer patients undergoing radiotherapy.Discover oncology · 2026Article
- Impact of Physical Frailty on Early Intolerance to CAPOX Chemotherapy in Patients With Colon, Rectal, and Gastric Cancer.Cancer medicine · 2026Observational
- Association of sarcopenia with survival and treatment response in brain metastasis of non-small cell lung cancer.Scientific reports · 2026Article
- Knowledge, attitude, and practice of nurses towards frailty syndrome: a multicenter cross-sectional survey in Fujian Province, China.Frontiers in medicine · 2026Article
- Investigating Factors Related to Length of Hospital Stay in Male Patients With Lung Cancer Undergoing Chemotherapy.Cureus · 2025Article
- Association of Sarcopenia With Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset Validation.Clinical lung cancer · 2025Article
- Relationship between physical function and quality of life based on treatment timing in patients with advanced lung cancer.Journal of physical therapy science · 2025Article
- The Association Between an Electronic Health Record (EHR)-Embedded Frailty Index and Patient-Reported Outcomes Among Patients with Metastatic Non-Small-Cell Lung Cancer on Immunotherapy: A Brief Report.The American journal of hospice & palliative care · 2024Article
- Frailty and Cancer Prognosis.Current oncology reports · 2024Review
- A comparison of frailty measures in population-based data for patients with colorectal cancer.Age and ageing · 2024Article
- Harnessing physical activity monitoring and digital biomarkers of frailty from pendant based wearables to predict chemotherapy resilience in veterans with cancer.Scientific reports · 2024Article
- The Impact of Frailty on Palliative Care Receipt, Emergency Room Visits and Hospital Deaths in Cancer Patients: A Registry-Based Study.Current oncology (Toronto, Ont.) · 2023Article
- Assessment of Frailty Index at 66 Years of Age and Association With Age-Related Diseases, Disability, and Death Over 10 Years in Korea.JAMA network open · 2023Article
- Persisting Gaps in Optimal Care of Stage III Non-small Cell Lung Cancer: An Australian Patterns of Care Analysis.The oncologist · 2023Article
- Comparison of clinical efficacy between chrono-chemotherapy and conventional chemotherapy in patients with non-small cell lung cancer.American journal of cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImproved assessment strategies are needed to individualize treatment for adults of all ages receiving palliative chemotherapy for non-small cell lung cancer (NSCLC). Our aim was to evaluate the utility of the Fried Frailty Index (FFI) and a cancer-specific geriatric assessment (GA) to predict chemotherapy toxicity and overall survival (OS).
methodsWe conducted a multi-site pilot study of 50 patients with newly diagnosed advanced NSCLC, age ≥ 18 years. All participants received carboplatin AUC 6, paclitaxel 200 mg/m
resultsAmong 50 participants, 48 received chemotherapy and were evaluable. The mean age was 68.5 y (range 42-86), 79% male, 85% KPS ≥80. The median OS was 8 months. Many (27%) met FFI criteria for frailty with ≥3 impairments. Impairments detected by the GA were common. In multivariable analyses both FFI ≥ 3 and GA toxicity risk score > 7 were independently associated with higher odds of toxicity (Odds ratio [OR] 7.0; 95% confidence interval [CI] 1.1-44.6 and OR 4.3; 95% CI 1.0-17.7, respectively) in first cycle chemotherapy. Neither score was associated with OS.
conclusionsFrailty predicts chemotherapy toxicity during first cycle. Frailty assessment may inform toxicity risk regardless of chronologic age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.